CSL shares smash through $100 again

Photo by Michael Dodge/Getty Images

CSL today rejoined the exclusive ranks of company’s with a share price above $100.

A short time ago, the shares were at $109.15, up 10% after a profit upgrade announcement.

CSL in August 2015 became the first ASX stock to hit $100 since the GFC but the blood products and flu vaccine group shares dropped below $100 earlier this month and closed yesterday at $99.12.

The other two $100 stocks on the ASX are vitamin maker Blackmores at $118.00 and bionic ear company Cochlear at $126.91.

CSL today upgraded its full year profit guidance after better than expected sales of its blood products.

The company now expects to report net profit after tax of $US800 million ($A1.06 billion) for the six months to the end of December.

Combining this with anticipated performance for the second half of 2017, CSL now expects to deliver profit growth of between 18% and 20%, up from the original forecast of 11%.

That would put the company on track to hit almost $US1.5 billion ($A1.9 billion) in profit for the 2017 financial year.

In August, CSL posted a 10% fall in full year net profit to $US1.24 billion ($A1.6 billion) after the costs of becoming the world’s second largest flu vaccine business.

The top 10 Australian company by market capitalisation last year bought a loss-making subsidiary of Swiss pharmaceutical multinational Novartis for $US275 million ($A357 million). The flu vaccine business is due to break even in 2018.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.